ICU Medical, Inc. (ICUI)

Environment story

ICU Medical discloses minimal quantitative environmental data. Scope 1, 2, and 3 emissions are not disclosed in the 10-K; no net-zero target year is stated. The company acknowledges climate-related physical risks (floods, droughts, storms, wildfires) and regulatory exposure (CSRD, California SB 253/261). Manufacturing relies heavily on oil/gas-derived resins and plastics; tariff impacts (2025: $33.6M incremental cost) reflect supply-chain vulnerabilities. No verified renewable electricity percentage disclosed. No major environmental controversies or fines identified in source documents. The company's ESG risk factors acknowledge evolving sustainability expectations but provide no credible decarbonization roadmap or emissions baselines, triggering penalties for undisclosed Scope 3 and missing net-zero commitment.

Social story

ICU Medical reports ~13,000 employees across 35+ countries (as of Dec 31, 2025). No CEO-to-worker pay ratio disclosed; no union-suppression activities or major strikes documented in source materials. Leadership diversity percentage not disclosed; company's 10-K references 'development of workforce' and 'tuition reimbursement' but provides no quantitative diversity metrics (gender, race/ethnicity) for executive or board levels. Supply-chain ethics: no modern slavery statement, conflict minerals policy, or high-risk geography audits disclosed. The company emphasizes competitive salaries, benefit packages, safety training, and collaborative culture; however, absence of formal DEI program disclosures, pay equity audits, and supply-chain human-rights certifications limits transparency and triggers penalties for undisclosed leadership diversity and missing supply-chain safeguards.

Governance story

ICU Medical does not disclose board independence percentage or share structure (single vs. dual-class). No lobbying expenditure or PAC contribution disclosures found in 10-K source material. No active antitrust, consumer-safety, or financial-fraud proceedings identified in provided documents. Company faces extensive FDA and EU Medical Devices Regulation compliance requirements; regulatory risk factors emphasize potential for warning letters, fines, consent decrees, and device recalls if manufacturing or marketing controls fail. Multiple references to post-market enforcement powers and compliance obligations suggest robust regulatory scrutiny but no reported violations or significant fines documented in the source. Governance risk disclosure is thorough on regulatory exposure but lacks transparency on board composition, share voting structure, and political spending—typical omissions in medical device manufacturer filings.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of ICU Medical, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open ICU Medical, Inc. in the app for interactive charts and portfolio building.

More in Healthcare